Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 24, 2022

Study Completion Date

April 24, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

BMS-984923

Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.

Trial Locations (1)

06520

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Yale University

OTHER